Vaccines (Oct 2022)

Designing an Epitope-Based Peptide Vaccine Derived from RNA-Dependent RNA Polymerase (RdRp) against Dengue Virus Serotype 2

  • Irma F. Wahongan,
  • Elly J. Suoth,
  • Fatimawali,
  • Saad Alhumaid,
  • Hawra Albayat,
  • Mohammed Aljeldah,
  • Basim R. Al Shammari,
  • Mutaib M. Mashraqi,
  • Ahmad A. Alshehri,
  • Tarek Sulaiman,
  • Safaa A. Turkistani,
  • Ameen S. S. Alwashmi,
  • Mohammed Garout,
  • Trina Ekawati Tallei,
  • Ali A. Rabaan

DOI
https://doi.org/10.3390/vaccines10101734
Journal volume & issue
Vol. 10, no. 10
p. 1734

Abstract

Read online

Dengue fever (DF) continues to be one of the tropical and subtropical health concerns. Its prevalence tends to increase in some places in these regions. This disease is caused by the dengue virus (DENV), which is transmitted through the mosquitoes Aedes aegypti and A. albopictus. The treatment of DF to date is only supportive and there is no definitive vaccine to prevent this disease. The non-structural DENV protein, RNA-dependent RNA Polymerase (RdRp), is involved in viral replication. The RdRp-derived peptides can be used in the construction of a universal dengue vaccine. These peptides can be utilized as epitopes to induce immunity. This study was an in silico evaluation of the affinity of the potential epitope for the universal dengue vaccine to dendritic cells and the bonds between the epitope and the dendritic cell receptor. The peptide sequence MGKREKKLGEFGKAKG generated from dengue virus subtype 2 (DENV-2) RdRp was antigenic, did not produce allergies, was non-toxic, and had no homology with the human genome. The potential epitope-based vaccine MGKREKKLGEFGKAKG binds stably to dendritic cell receptors with a binding free energy of −474,4 kcal/mol. This epitope is anticipated to induce an immunological response and has the potential to serve as a universal dengue virus vaccine candidate.

Keywords